HAVCR2 and chronic myelogenous leukemia, BCR-ABL1 positive: Therefore, much more clinical studies are required to examine the expression of TIM-3 in other immune cell types in CML as well and establish its role in formation, therapy resistance, relapse of CML, and immune scoring in this malignancy.